Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
June 09, 2025 16:05 ET | Source: Lyell Immunopharma, Inc Mark J.…
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
June 06, 2025 16:07 ET | Source: Restem MIAMI, June 06, 2025…
Highstar Unveils Next-Gen Tabless Cell Series at The Battery Show Europe 2025
STUTTGART, Germany, June 5, 2025 /PRNewswire/ -- Highstar launched its next-generation Tabless Cell…
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE…
Alkegen Enters Full Production of EV Battery Fire Protection Aerogels
World's Largest Supplier of Cell Spacers Delivering OEMs a Full Portfolio of…
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease…
Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…